MedTrace Logo

Low Dose Atropine for Symptomatic Vitreous Floaters

NCT06174935 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-12-18

No results posted yet for this study

Summary

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Conditions

  • Vitreous Floaters

Interventions

DRUG

0.01% atropine ophthalmic drop

0.01% atropine ophthalmic drop will be applied daily to the affected eye

Sponsors & Collaborators

  • Jeanette Du

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-06-01
Completion
2024-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06174935 on ClinicalTrials.gov